Evidence map›Paper›PMID 27209004›Full record

ArticleJournal of fluorescence2016

Studies of DNA Aptamer OliGreen and PicoGreen Fluorescence Interactions in Buffer and Serum.

John G Bruno, Jeffrey C Sivils

Open access · greenAbstract read
In one paragraph

Article in Journal of fluorescence, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

John G BrunoOperational Technologies Corporation, 4100 NW Loop 410, Suite 230, San Antonio, TX, 78229, USA. john.bruno@otcorp.com.
Jeffrey C SivilsOperational Technologies Corporation, 4100 NW Loop 410, Suite 230, San Antonio, TX, 78229, USA.
Operational Technologies Corporation (United States) · US

Funding

Development of Anti-OLAM Aptamers as Novel Analgesics (Phase 2)R44GM101712 · NIGMS · OPERATIONAL TECHNOLOGIES CORPORATION · PI BRUNO, JOHN G · 2015 to 2016
$999k
Development of Anti-OLAM Aptamers as Novel AnalgesicsR43GM101712 · NIGMS · OPERATIONAL TECHNOLOGIES CORPORATION · PI BRUNO, JOHN G · 2012 to 2012
$147k
NCI NIH HHS HHSN261201300075CNIGMS NIH HHS R43 GM101712NIGMS NIH HHS R44 GM101712
6 · The paper itself

Abstract

Spectrofluorometric and emission peak titration and timed studies of OliGreen (OG) and PicoGreen (PG) were conducted in Tris EDTA (TE) buffer, pooled rat and fetal bovine serum with two different aptamers of 72 and 192 bases in length to determine if OG or PG were suitable for aptamer pharmacokinetic (PK) studies in sera. Results indicated that OG and PG detected the single-stranded (ss) and double-stranded (ds) stem-loop structures of the two aptamers quite well in TE with reliable standard curves having exponential character (or several linear detection regions) up to 1 μg/ml of aptamer DNA with detection limits of ~1 ng/ml. The intensity of OG and PG staining appeared to correlate with the number and percentage of ss and ds bases in each aptamer. OG and PG fluorescence in pooled rat serum or fetal bovine serum (FBS) did not titer as a function of DNA aptamer concentration from 1 μg/ml to 1 ng/ml. This lack of OG or PG aptamer assays in serum is contrary to most published reports of OG or PG assays for ss antisense oligonucleotides, ds PCR amplicons or other types of DNA in serum or plasma. Further studies suggested that the lack of OG and PG assay titration in serum might not be entirely due to aptamer degradation from nucleases in serum since the fluorescence signals in serum appeared relatively stable over time from 30 min to 4 hours. A hypothesis is presented which attributes the inability of OG or PG to assay aptamers in serum to a combination of high blue-green autofluorescence in serum with possible serum nuclease degradation of aptamers over time and the changing aptamer to serum protein ratio coupled to nonspecific binding of serum proteins to aptamers thereby possibly changing aptamer conformations as a function of aptamer concentration during titration experiments.

Indexed as

AnimalsAptamers, NucleotideBuffersCattleRatsSerumSpectrometry, FluorescenceAptamers, NucleotideBuffersAptamerDouble-strandedElectrophoresisOliGreenPicoGreenSerumSingle-stranded

Identifiers

PMID27209004
PMCPMC4958561
OpenAlexW2405122749

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.